» Articles » PMID: 20043032

Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience

Overview
Journal PLoS Curr
Specialty General Medicine
Date 2010 Jan 1
PMID 20043032
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

This work contributes informed estimates to the current debate about the pandemic (H1N1) 2009 mass immunization program's economic merits. We performed a cost-utility analysis of the (H1N1) 2009 mass immunization program in Ontario, Canada's most populous province. The analysis is based on a simulation model of a pandemic (H1N1) 2009 outbreak, surveillance data, and administrative data. We consider no immunization versus mass immunization reaching 30% of the population. Immunization program costs are expected to be $118 million in Ontario. Our analysis indicates this program will reduce influenza cases by 50%, preventing 35 deaths, and cutting treatment costs in half. A pandemic (H1N1) 2009 immunization program is likely to be highly cost-effective.

Citing Articles

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.

Thommes E, Kruse M, Kohli M, Sharma R, Noorduyn S Hum Vaccin Immunother. 2016; 13(4):867-876.

PMID: 27858509 PMC: 5404371. DOI: 10.1080/21645515.2016.1251537.


Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemics.

Perez Velasco R, Praditsitthikorn N, Wichmann K, Mohara A, Kotirum S, Tantivess S PLoS One. 2012; 7(2):e30333.

PMID: 22393352 PMC: 3290611. DOI: 10.1371/journal.pone.0030333.

References
1.
Postma M, Jansema P, van Genugten M, Heijnen M, Jager J, de Jong-van den Berg L . Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs. 2002; 62(7):1013-24. DOI: 10.2165/00003495-200262070-00003. View

2.
Postma M, Baltussen R, Heijnen M, de Berg L, Jager J . Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence. Drugs Aging. 2000; 17(3):217-27. DOI: 10.2165/00002512-200017030-00005. View

3.
Turner D, Wailoo A, Cooper N, Sutton A, Abrams K, Nicholson K . The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine. 2005; 24(7):1035-43. DOI: 10.1016/j.vaccine.2004.12.033. View

4.
Mittmann N, Trakas K, Risebrough N, Liu B . Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999; 15(4):369-76. DOI: 10.2165/00019053-199915040-00004. View

5.
Kwong J, Stukel T, Lim J, McGeer A, Upshur R, Johansen H . The effect of universal influenza immunization on mortality and health care use. PLoS Med. 2008; 5(10):e211. PMC: 2573914. DOI: 10.1371/journal.pmed.0050211. View